Prof. Hong is President of the World Society for Reconstructive Microsurgery, Professor at Asan Medical Center in Korea, and Adjunct Professor at Georgetown University in the United States. Widely regarded as a global authority in reconstructive and super-microsurgery, he has published extensively, trained surgeons worldwide, and consistently advocated for technologies that advance surgical precision and outcomes. He brings world-class clinical leadership and global credibility to support MediThinQ's education programs, clinical adoption, and ongoing innovation around SHIYA 20.

SHIYA 20 is among the first fully integrated 3D digital microsurgery platforms, unifying visualization, ergonomics, and data capture into one surgeon-centered system. Over the past year, Prof. Hong's intensive hands-on experience with SHIYA 20 in live surgeries and global training programs has provided meaningful real-world validation for surgeons and hospitals considering next-generation digital visualization technologies.

"MediThinQ is shaping the next era of microsurgery," said Prof. Hong. "With a full range of low- to high-power magnification (up to 20x), true 3D digital data, and real ergonomic freedom, SHIYA 20 gives surgeons the clarity, comfort, and connectivity we have long needed. These elements are essential for safer and more precise microsurgery, not just conveniences. SHIYA 20 brings them together in a single platform, opening the door to a more efficient, data-driven, and future-ready operating room. I'm excited to help accelerate its global impact."

Mr. Seungjoon Im, Founder & CEO of MediThinQ, said: "Prof. Hong's decision to join MediThinQ underscores the clinical trust we have earned from the surgical community. His leadership will help advance SHIYA 20's role in modern microsurgery and guide us as we expand our digital ecosystem to support surgical treatment, education, collaboration, and future AI-driven innovation."

SHIYA 20 is MediThinQ's flagship digital microsurgery platform, integrating a 3D digital microscope, 3D exoscope, SCOPEYE wearable visor, and real-time recording into a unified workflow. Developed over years of close collaboration with surgeons, it enhances clarity, ergonomics, and efficiency in the operating room. Its combination of digital workflow integration and clinical validation has positioned SHIYA 20 as a new standard in modern microsurgery.

With the platform now gaining momentum, MediThinQ is accelerating its commercial expansion. Recent milestones include securing exclusive distribution agreements in the Taiwan region, Singapore, and Malaysia markets. The company also received regulatory approval for 3D SCOPEYE in Mainland China through its partnership with Sinopharm, enabling nationwide hospital access.

MediThinQ is a South Korea–based medical technology company focused on XR and 3D surgical visualization. Through solutions like SHIYA 20 and SCOPEYE, the company enables more precise, ergonomic, and digitally connected surgical environments worldwide.

MediThinQ's XR solutions are the world's first developed specifically for medical use in live surgery. They deliver real-time, high-definition visualisation by bringing images and information from multiple displays directly to the surgeon's eyes, enhancing focus and precision during procedures. With regulatory approvals in US, Europe, and South Korea — and over 10,000 tests and live demonstrations across hospitals in all major markets — the technology is redefining modern surgical practices.

A major milestone in MediThinQ's global commercialisation was achieved through an exclusive distribution agreement with a leading global medtech company, first in the US and later in Europe. Building on this momentum, the partnership with Sinopharm fills the final major gap in its global footprint by accelerating adoption in China's vast healthcare system.

Mr Seungjoon Im, Founder & CEO of MediThinQ, stated: "With Sinopharm as our strong partner, we're excited to be the first to introduce this groundbreaking technology to Chinese surgeons and accelerate its adoption. This is just the beginning of our journey in China, and we look forward to collaborating with Sinopharm to bring even more of our latest innovations to the market." 

"Sinopharm has been at the forefront of China's rapid adoption of the world's most advanced medical technologies, and wearable surgical displays are no longer experimental — they are becoming a new standard in modern surgery," said Mr Wang Yiran, Chairman of Sinopharm Group Med-Tech Co., Ltd.. "This innovation will not only enhance ergonomics for healthcare professionals and improve operating room efficiency, but also fundamentally transform how surgeons learn, train, and perform procedures. As the exclusive distributor of MediThinQ's XR surgical displays in China, Sinopharm is committed to playing a role in this transformation."

MediThinQ is supported by VentureBlick, a go-global partner for healthcare innovation. Chris Lee, Founder & CEO of VentureBlick said: "Bringing local medical technology to the global stage has always been our mission, and MediThinQ is a standout example of that vision in action. VentureBlick is proud to have supported MediThinQ's global expansion — from US to Europe, and now into China — laying a strong foundation to accelerate its worldwide adoption and long-term growth."

MediThinQ's momentum is powered by ongoing R&D breakthroughs, including the world's smallest portable 3D microscope and a next-generation digital loupe. It recently completed a successful USD 8.8 million Series B round, fuelling further innovation and market reach. The new partnership in China strengthens its leadership and marks a major step toward global expansion.

The SCOPEYE 3D Micro Surgery Solution comprises the SCOPEYE Eyes Up wearable display, the 3D Microvision, a light and portable high-performance 3D digital microscope, and the 3D AddON, a device that elevates conventional 2D microscopes to advanced 3D capabilities. Offering exceptional performance, mobility, and space efficiency while maintaining a minimalist design aesthetic, it empowers surgeons to perform 3D procedures wherever needed. Its portability makes it ideal for a wide range of applications, including microsurgery, plastic surgery, dental procedures, ophthalmology, hair transplant surgery, and dermatology.

The benefits of the SCOPEYE 3D Micro Surgery Solution are manifold. With high-resolution 3D optics, surgeons gain unparalleled visual clarity and depth perception, enhancing their precision and accuracy during procedures. Additionally, the solution offers significant cost efficiencies, maximised ergonomic comfort, and advanced features such as 3D recording and training capabilities, further enhancing patient care and surgical outcomes.

Propelling MediThinQ's growth forward, Chris Lee, Founder & CEO of VentureBlick, assumes the role Chairman of the Board of MediThinQ, marking a pivotal moment in MediThinQ's journey. With a remarkable 30-year career spanning top global pharmaceutical and medtech companies, Chris brings extensive experience and leadership to the table.

In a strategic move to deepen their collaboration, MediThinQ and VentureBlick have entered a cross-ownership agreement. With this arrangement, both companies will own stakes in each other's shares, reaffirming their commitment to mutual advancement and success.

MediThinQ and VentureBlick's partnership began when MediThinQ joined VentureBlick's Super Incubator programme. With VentureBlick's support, MediThinQ achieved key milestones. Now, their bond has deepened even further, marking a significant moment for both companies.

Chris Lee, Founder & CEO of VentureBlick said: "MediThinQ's solutions deliver tangible medical value, and we are thrilled to collaborate with them on an even deeper level to enhance surgical visualisation, ultimately leading to improved patient outcomes. Our partnership will accelerate MediThinQ's growth further and pave the way for pioneering advancements in the field of extended reality for surgical applications."

Seungjoon Im, Founder & CEO of MediThinQ, said: "Our SCOPEYE 3D Mirco Surgery Solution sets a new standard and is a strong addition to our offerings as we ramp up our global commercialisation efforts. We're grateful to Chris for accepting the role of Chairman of our Board. With his vast international experience, he is the undoubtedly the ideal person to bring MediThinQ to new heights."

MediThinQ's journey from a visionary startup to a global leader is marked by significant milestones. As the first Asian startup to globally launch XR surgical displays, the company has garnered attention and accolades worldwide. Securing major deals with industry giants in the USA, Japan, Australia, and Europe, is a testament to the quality and effectiveness of MediThinQ's offerings, positioning the company as a frontrunner in the global healthcare landscape.

MediThinQ is currently raising its Series B fund while exploring IPO options in Korea, Singapore, Hong Kong SAR, and North America. It is setting the stage for potential early exits through strategic acquisitions or accelerated commercial growth.

SINGAPORE, May 8, 2024 /PRNewswire/ -- VentureBlick announces the launch of Discovery, a groundbreaking networking platform designed to connect healthcare innovators, advisors, investors, distributors, partners, and service providers worldwide.

Healthcare innovation is often associated with high barriers and risks, necessitating more cross-border and cross-sector collaboration for global impact. Discovery is the first-ever platform bringing together key stakeholders in healthcare innovation under one virtual roof.

It is free to join Discovery, which is line with the platform's mission to foster openness, enhance visibility, and facilitate connections throughout the ecosystem.

Since its soft launch a few weeks ago, Discovery has attracted close to 3,000 members from across 50 countries, underscoring its global appeal and potential for growth.

Innovators, investors, and distributors alike stand to benefit from Discovery's comprehensive suite of tools and resources. Innovators can showcase their breakthrough technologies on a global stage, connect with potential partners and investors beyond their home market, and access essential resources for growth and expansion. Investors can identify promising investment opportunities, gain valuable market intelligence, and engage directly with industry experts. Distributors can expand their product portfolios into new territories or new geographies and forge new partnerships.

One of Discovery's distinguishing features is its exclusive access to a carefully curated list of advisors. These advisors are either practicing clinicians or industry experts with domain expertise and an innovative mindset, chosen to be part of the global VB Advisory Network. They undergo rigorous vetting to provide innovators with invaluable real-world feedback, clinical insights, and critical resources. VentureBlick is committed to prioritising medical value when it comes to validating and supporting healthcare innovation, making the VB Advisory Network an essential component of this mission.

Advisors can leverage Discovery to stay informed about the latest innovations in their specialty areas, connect with like-minded peers and industry experts, monetise their expertise through paid consulting engagements, and explore business opportunities.

Chris Lee, Founder & CEO of VentureBlick, expressed his enthusiasm for the launch of Discovery, stating, "Discovery was created with the simple purpose of helping people within the healthcare innovation ecosystem find each other and work together instead of relying on their own professional network, which can be limited."

Discovery offers a range of features tailored to meet the diverse needs of its members, including user profiles and filtered directories, and direct messaging capabilities. More features including Open Innovation Search, 1-to-1 expert call on-demand, smart matching, and open Q&A forum will soon be introduced, further enhancing the platform's utility and effectiveness.

For more information about VentureBlick and Discovery, please visit www.ventureblick.com.

About VentureBlick

VentureBlick is an all-in-one healthcare innovation engine, driving connections across borders to propel local innovations onto the global stage. Its suite of services includes the Super Incubator, Consulting, and the innovative Discovery networking platform. VentureBlick fosters collaboration among innovators, clinicians, investors, and ecosystem partners worldwide. Boasting a seasoned team and a network of 2,500 healthcare experts from 60 countries, VentureBlick is committed to prioritising medical value and driving impactful open innovation. Headquartered in Singapore and operating in Korea, Germany, India, and China, VentureBlick has a track record of guiding startups, SMEs, and corporations achieve their milestones through global market mapping, medical validation, market entry strategies, technology scouting, healthcare partnership, and beyond. Discover more at www.ventureblick.com.

In tandem, MediThinQ has secured a multimillion-dollar investment from JLK Technology, a Singapore-headquartered medical devices manufacturer, who will also help accelerate MediThinQ's mass production as its appointed manufacturer.

MediThinQ's XR solutions present critical information directly in from of the surgeon's eyes, eliminating the need to divert attention to screens. The first of its kind in revolutionising how medical information is accessed in live surgeries, they are backed by best-in-class image fidelity, latency, reliability, and equipment compatibility.

In the United States and Japan, the world's two largest healthcare markets, MediThinQ's products will be exclusively distributed by Medtronic, underscoring global industry leaders' acknowledgement of the quality and effectiveness of MediThinQ's offerings. This strategic partnership represents a significant milestone in MediThinQ's path toward full-scale commercialisation and global expansion.

Mr Seungjoon Im, Founder & CEO of MediThinQ, expressed his excitement, stating, "We are proud of the groundbreaking technology we've cultivated over the past six years, which sets a new standard in the market. It's even more rewarding to see our innovations making their way into operating theatres worldwide. We extend our heartfelt appreciation to all our partners who have joined us on this transformative journey, and to VentureBlick for orchestrating these pivotal moments and connecting the dots behind the scenes."

Earlier this year, MediThinQ joined VentureBlick's Super Incubator programme – a unique blend of incubator, accelerator, and venture builder, offering tailored support for healthcare startups. VentureBlick has since played a crucial role in elevating MediThinQ's global brand recognition, enhancing negotiation outcomes, raising funds, and positioning the company for continued success.

MediThinQ's flagship products, Scopeye and MetaSCOPE, already hold regulatory approvals in key markets including the US (FDA), Europe (CE), Japan (PMDA), and Korea (KFDA). The technology has also been recognised as one of the top winners at the Medtronic APAC Innovation Challenge in 2022 and received a gold medal at the 2023 Edison Awards.

Looking ahead, MediThinQ is gearing up to launch its next product line targeting the burgeoning Chinese market. It is also exploring applications beyond the medical space, including a collaboration with one of the largest conglomerates in Korea. MediThinQ is currently raising its Series B fund while exploring IPO options in Singapore, Hong Kong, and North America. It is setting the stage for potential early exits through strategic acquisitions or accelerated commercial growth.

About MediThinQ

MediThinQ is a Korea-based startup specialising in medical imaging equipment for surgery. The company's XR surgical displays, including Scopeye and MetaSCOPE, are at the forefront of technological innovation, providing surgeons with unparalleled information management and access in the operating theatre. With regulatory approvals in major markets and strategic distribution partnerships, MediThinQ is poised for global success.

About VentureBlick

VentureBlick is a catalyst for global healthcare innovation with a strong focus on identifying and delivering true medical value. It connects and mobilises innovators, clinicians, investors, and ecosystem partners to create real, collective impact through the VentureBlick Super Incubator, VentureBlick Consulting, and VentureBlick Discovery. The company distinguishes itself through a team with deep healthcare roots and diverse advisor network of 2,000+ clinicians and healthcare professionals from 50+ countries and 30+ specialties. Headquartered in Singapore with presences in Korea, Germany, and India, VentureBlick fosters collaboration among innovators, investors, advisors, distributors, and ecosystem partners worldwide to make a significant impact in healthcare. Join us in shaping the future of healthcare at www.ventureblick.com.

SINGAPORE, July 5, 2023 /PRNewswire/ -- VentureBlick, a global venture platform for healthcare innovation, announces the successful closure of its first two deals, securing a total of US$2.6 million for two startups despite a challenging funding environment. This achievement is a testament of VentureBlick's distinctive approach of engaging the global medical community to validate, support, and invest in early-stage healthcare startups.

Exceeding expectations, VentureBlick raised US$1.6 million for NousQ, a Singapore-based startup revolutionizing glue ear surgery with the world's first smart robotic handheld device. This oversubscription, surpassing the initial target by 60%, demonstrates investors' strong confidence in medical innovations that address real medical needs and possess a clear clinical use case. The second deal, for a China-based healthcare startup, closed at over US$1 million. Both startups were put through a three-step vetting process, which includes systematic review by medical and industry experts from respective areas across the globe, before they were listed on the platform.

Dr Lynne Lim, Founder & CEO of NousQ, expressed her enthusiasm, stating, "We are thrilled to have surpassed our fundraising target on the VentureBlick platform. This US$1.6 million bridge funding is a significant step towards our ultimate fundraising goal of US$5.5 million for our current ongoing Series A fundraise. Getting such positive responses from fellow doctors and investors around the world means a lot to our team. Equally exciting is the opportunity to tap into VentureBlick's extensive healthcare expertise and resources."

Building on this success, VentureBlick is evolving its business model into a 'Super Incubator' model, which provides an end-to-end, fully customizable solution to help build, test, and market medtech innovations, with successful exits or commercialisation as the ultimate goal.

Chris Lee, Founder & CEO of VentureBlick, emphasized the importance of this evolution, stating, "Medtech presents unique challenges and opportunities. We found that existing venture support models like incubator or accelerator programs often lack industry-specific focus or cover only certain aspects or growth stages. This leaves significant gaps, uncertainties, and risks to all stakeholders involved in a startup's development. Super Incubator for VentureBlick is not another of those programs, but how we are going to redefine medtech venture building. What we offer medtech startups is a tailored medtech-centric ecosystem and full-slate support model to enable their innovations to reach the market in the shortest time possible and create most tangible impact."

VentureBlick will officially launch its Super Incubator in September 2023 and is currently raising funds for the new model. The Super Incubator promises to streamline the startup journey from ideation and testing to venture building and market success. Its comprehensive offering includes product demand validation at the very beginning, fundraising, design and manufacturing, healthcare partnerships, product trial and assessment, health economics and reimbursement strategy, as well as market mapping and access.

As part of its new model, VentureBlick is also launching its medical advisory business, offering expertise in evaluating investments or M&A deals from a medical perspective on behalf of corporate ventures, VCs, or government bodies. One of the largest corporate conglomerates in the world has retained VentureBlick to assess its potential investment deals in the healthcare sector. They will tap into VentureBlick's global advisory network, which consists of more than 1,000 advisors who have been individually screened and vetted from more than 50 countries covering over 30 specialty areas. The advisor pool will be further expanded to 3,000 by the end of 2023.

With a strong foundation established and an impressive pilot programme, VentureBlick is well-positioned to continue driving and supporting innovation in the healthcare sector with its new business model, ultimately improving healthcare outcomes worldwide.

About VentureBlick

VentureBlick is a Super Incubator for medtech startups, providing a fully customisable one-stop solution to build, test, and market innovations with the ultimate goal of successful exits or commercialisation. Leveraging its global advisor network, strong in-house capabilities, and specialised partners, VentureBlick streamlines the startup journey, from ideation and testing to venture building and market success. The company is headquartered in Singapore with a presence in Australia, China, Germany, India, Korea, and USA. Join us in shaping the future of healthcare at www.ventureblick.com.

SINGAPORE, Nov. 15, 2022 /PRNewswire/ -- VentureBlick, a fundraising platform matching healthcare startups with medical investors, has launched its worldwide search to identify promising healthcare startups for the medical community to evaluate, advise, and fund. Only startups that receive endorsement from a large group of medical professionals with relevant domain expertise will have the chance to raise funds through the platform.

For healthcare startups, many of their ultimate customers are medical professionals – physicians, clinicians, and healthcare industry professionals – who could also be their investors and advisors. The platform enables the global medical community to evaluate medical investment opportunities in a systematic, large-scale, and cross-border manner. The fundraising process doubles up as a market validation process, providing startups funding, market insight, and customer validation in one go.

The Healthcare Startup Search takes place till January 4, 2023 at www.ventureblick.com. It's open to early-stage startups with innovative solutions for all segments of healthcare and are seeking to raise up to US$5M. After screening and due diligence, shortlisted startups will be showcased on VentureBlick's fundraising platform when it launches in early 2023. Once the startups achieve a certain level of investment from medical investors, participation will be open to general investors – accredited investors, who are keen on investing in healthcare but do not have medical background. VentureBlick's unique mechanism provides additional access, as well as enhances both the quality and volume of investment for the healthcare industry.

Chris Lee, Founder & CEO of VentureBlick, who is a top global healthcare executive previously with Medtronic, Bayer, BMS, and MSD, said: "After months of preparation, we are finally ready to kick off this global search. We want to give the most promising startups the spotlight they deserve and match them to healthcare professionals who are interested in investing in and nurturing them. Our goal is to connect startups to the right people and the right resources, so that they get things right in the shortest time possible. This is especially important before they start their long development journey."

The first 10 startups to be shortlisted from this search will receive a marketing pack worth US$10,000, which includes support to help them optimize their pitch deck, produce a video, and polish their pitch narratives before they are presented to investors. This is in addition to the funding they may receive when showcased on the VentureBlick platform.

About VentureBlick

VentureBlick aims to transform healthcare fundraising through its fundraising platform and professional community. It matches early-stage healthcare startups with medical investors– the startups' potential customers – who can validate ideas, support, and fund, without diluting startup control. Its professional community also provides advisory services, network opportunities, and need-based operational services to help startups grow.

Follow us on LinkedIn or visit www.ventureblick.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ventureblick-launches-global-search-for-healthcare-startups-most-endorsed-by-the-medical-community-301676607.html

SINGAPORE, Nov. 15, 2022 /PRNewswire/ -- VentureBlick, a fundraising platform matching healthcare startups with medical investors, has launched its worldwide search to identify promising healthcare startups for the medical community to evaluate, advise, and fund. Only startups that receive endorsement from a large group of medical professionals with relevant domain expertise will have the chance to raise funds through the platform.

For healthcare startups, many of their ultimate customers are medical professionals – physicians, clinicians, and healthcare industry professionals – who could also be their investors and advisors. The platform enables the global medical community to evaluate medical investment opportunities in a systematic, large-scale, and cross-border manner. The fundraising process doubles up as a market validation process, providing startups funding, market insight, and customer validation in one go.

The Healthcare Startup Search takes place till January 4, 2023 at www.ventureblick.com. It's open to early-stage startups with innovative solutions for all segments of healthcare and are seeking to raise up to US$5M. After screening and due diligence, shortlisted startups will be showcased on VentureBlick's fundraising platform when it launches in early 2023. Once the startups achieve a certain level of investment from medical investors, participation will be open to general investors – accredited investors, who are keen on investing in healthcare but do not have medical background. VentureBlick's unique mechanism provides additional access, as well as enhances both the quality and volume of investment for the healthcare industry.

Chris Lee, Founder & CEO of VentureBlick, who is a top global healthcare executive previously with Medtronic, Bayer, BMS, and MSD, said: "After months of preparation, we are finally ready to kick off this global search. We want to give the most promising startups the spotlight they deserve and match them to healthcare professionals who are interested in investing in and nurturing them. Our goal is to connect startups to the right people and the right resources, so that they get things right in the shortest time possible. This is especially important before they start their long development journey."

The first 10 startups to be shortlisted from this search will receive a marketing pack worth US$10,000, which includes support to help them optimize their pitch deck, produce a video, and polish their pitch narratives before they are presented to investors. This is in addition to the funding they may receive when showcased on the VentureBlick platform.

About VentureBlick

VentureBlick aims to transform healthcare fundraising through its fundraising platform and professional community. It matches early-stage healthcare startups with medical investors– the startups' potential customers – who can validate ideas, support, and fund, without diluting startup control. Its professional community also provides advisory services, network opportunities, and need-based operational services to help startups grow.

Follow us on LinkedIn or visit www.ventureblick.com

Chris Lee aims to transform healthcare fundraising through VentureBlick's fundraising platform and professional community

SINGAPORE, Sept. 1, 2022 /PRNewswire/ -- Chris Lee, one of the most experienced healthcare executives having held senior positions including president of Medtronic Asia Pacific and head of Bayer Healthcare Asia Pacific, today announced his new role as the founder and CEO of VentureBlick, a platform aiming to transform healthcare fundraising by matching healthcare startups with medical investors. Unlike traditional investors, medical investors who join the platform, namely physicians, clinicians, hospital administrators,and healthcare industry professionals with deep domain expertise and user experience, will provide unparalleled value to startups – not just as their investors, but also as their advisors and future customers.

As an early-stage startup aiming for an IPO, VentureBlick is dedicated to helping early-stage healthcare startups get funding, product validation, and market insights from medical investors – their ultimate customers – through its fundraising platform and professional community. In turn, medical investors get the chance to play an active role in developing the healthcare ecosystem and invest in the latest innovations in healthcare – an area they are most familiar with.

Healthcare startups face unique challenges such as long product development time and high barriers to market access due to quality, regulatory, and clinical requirements. These are in addition to two critical success factors faced by every startup founder: securing funding without losing focus on their product and validating if their product is what customers really want.

VentureBlick's platform will allow medical investors to systematically evaluate, advise and invest in healthcare startups. Once the startup idea is endorsed by a certain level of medical investors, it will be open to other accredited investors who might not have medical knowledge but are interested in healthcare investment. Its unique fundraising mechanism will enable founders to raise funds without worrying about losing control over their startup, giving them peace of mind. The professional community will also give founders the support they need to develop a product the market really needs. In addition, VentureBlick will partner with a broader group of institutional investors, helping them screen and de-risk startups with its unique model at the early stage before the startups are ready to collaborate with VCs or PEs for later-stage development. 

Chris Lee said, "Healthcare startups deserve a more specialized and effective support system because the ecosystem they operate in is very unique. How can we help them get market insights and customer feedback earlier in their journey? Is there a better way to motivate all stakeholders to work together and accelerate innovation? This inspired me to create a platform where startups can meet their future customers so they can nurture new innovations together. After 30 years in the healthcare industry, I see a huge unmet need here and hope VentureBlick can help narrow the gap."

VentureBlick has a presence in Australia, Korea, Singapore, and the USA. It is in the midst of establishing a presence in China by early next year. Its fundraising platform is targeted to launch in early 2023, and healthcare startups and medical professionals who are interested may pre-register their interest at www.ventureblick.com. In addition, VentureBlick will launch its own venture capital fund, the VB Healthcare Fund, to invest in promising healthcare startups.

Lee has extensive experience across multiple healthcare sectors including pharmaceuticals, medical devices, animal health, diagnostics, and consumer healthcare. He has worked in more than 10 countries, holding senior regional and country leadership roles at Merck (MSD), Bristol Myers Squibb, Bayer, and most recently Medtronic. Lee is among few Asians appointed to Executive Committee positions in both top pharmaceutical and medtech companies. He has a strong track record across M&As, strategic partnerships, new market expansion, and startup incubation.

Lee is an active advocate of inclusive leadership and workplace happiness. He has won multiple management awards including Most Respected CEO from Great Place to Work for three consecutive years (2020-2022) and Executive of the Year 2021 by Singapore Business Review.

About VentureBlick

VentureBlick aims to transform healthcare fundraising through its fundraising platform and professional community. Its fundraising platform matches early-stage healthcare startups with medical investors (physicians, clinicians, and industry experts) – the startups' potential customers – who can validate ideas, support, and fund, without diluting startup control. Its professional community provides the most practical and specialized advisory service, network opportunities, and need-based operational services to help the startups grow. It is the only fundraising platform that helps healthcare startups get funding, market insights, and customer endorsement, all in one go.

Follow us on LinkedIn or visit www.ventureblick.com

VentureBlick Media Contact / Investor Relations Inquiries

Elliza Yusof
Elliza.yusof@ventureblick.com
+65 9108 3101